Akums Drugs and Pharmaceuticals · NSE: AKUMS · BSE: 544222
Q2 FY26 results · Jul–Sep 2025
Akums Drugs and Pharmaceuticals reported revenue from operations of ₹1,017.53 crore (down 1.5% from Q2 FY25) and net profit of ₹42.70 crore (down 35.9% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,017.53 | 1,033.09 | −1.5% | 1,024.03 | −0.6% |
| Other income | 32.37 | 13.47 | +140.3% | 26.73 | +21.1% |
| Total income | 1,049.89 | 1,046.56 | +0.3% | 1,050.76 | −0.1% |
| Profit before tax | 65.67 | 91.59 | −28.3% | 95.65 | −31.3% |
| Net profit for the period | 42.70 | 66.65 | −35.9% | 64.69 | −34.0% |
| Attributable to shareholders of the company | 40.78 | 65.21 | −37.5% | 63.48 | −35.7% |
| EPS, basic (₹) | 2.66 | 4.37 | −39.1% | 4.15 | −35.9% |
| Net margin (%) | 4.2 | 6.5 | 6.3 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 309.31 | 328.35 | −5.8% | 332.44 | −7.0% |
| Other income | 27.08 | 32.12 | −15.7% | 28.55 | −5.2% |
| Total income | 336.39 | 360.47 | −6.7% | 361.00 | −6.8% |
| Profit before tax | 31.20 | 61.62 | −49.4% | 59.51 | −47.6% |
| Net profit for the period | 23.46 | 50.37 | −53.4% | 44.87 | −47.7% |
| EPS, basic (₹) | 1.53 | 3.38 | −54.7% | 2.93 | −47.8% |
| Net margin (%) | 7.6 | 15.3 | 13.5 |
Consolidated
- Filed with BSE
- 13 Nov 2025, 17:15 IST
- Board meeting
- 13 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2025, 17:15 IST
- Board meeting
- 13 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE